Atara Biotherapeutics Q1 2024 GAAP EPS $(0.23) Beats $(0.25) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics reported Q1 2024 GAAP EPS of $(0.23), surpassing the analyst consensus estimate of $(0.25) by 8 percent.
May 09, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics reported a smaller than expected quarterly loss for Q1 2024, with an EPS of $(0.23) against an estimate of $(0.25).
Beating earnings estimates typically has a positive impact on a company's stock price in the short term as it indicates better financial health and performance than expected by the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100